Related Experiment Video
Updated: Mar 31, 2026
Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
Published on: September 27, 2024
Nanoparticle-Mediated Target Delivery of TRAIL as Gene Therapy for Glioblastoma
Kui Wang1, Forrest M Kievit2, Mike Jeon1
1Department of Materials Science and Engineering, University of Washington, Seattle, WA, 98195, USA.
Abstract:
Human tumor necrosis factor α-related apoptosis-inducing ligand (TRAIL) is an attractive cancer therapeutic because of its ability to induce apoptosis in tumor cells while having a negligible effect on normal cells. However, the short serum half-life of TRAIL and lack of efficient in vivo administration approaches have largely hindered its clinical use. Using nanoparticles (NPs) as carriers in gene therapy is considered as an alternative approach to increase TRAIL delivery to tumors as transfected cells would be induced to secrete TRAIL into the tumor microenvironment. To enable effective delivery of plasmid DNA encoding TRAIL into glioblastoma (GBM), we developed a targeted iron oxide NP coated with chitosan-polyethylene glycol-polyethyleneimine copolymer and chlorotoxin (CTX) and evaluated its effect in delivering TRAIL in vitro and in vivo. NP-TRAIL successfully delivers TRAIL into human T98G GBM cells and induces secretion of 40 pg mL(-1) of TRAIL in vitro. Transfected cells show threefold increased apoptosis as compared to the control DNA bound NPs. Systemic administration of NP-TRAIL-CTX to mice bearing T98G-derived flank xenografts results in near-zero tumor growth and induces apoptosis in tumor tissue. Our results suggest that NP-TRAIL-CTX can potentially serve as a targeted anticancer therapeutic for more efficient TRAIL delivery to GBM.
Insights
Targeted nanoparticles deliver tumor necrosis factor α-related apoptosis-inducing ligand (TRAIL) to glioblastoma cells, enhancing apoptosis and inhibiting tumor growth in vivo. This novel approach improves TRAIL delivery for potential cancer therapy.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Cancer Therapeutics
Background:
- Human tumor necrosis factor α-related apoptosis-inducing ligand (TRAIL) shows promise for cancer therapy due to its tumor-specific apoptosis induction.
- Clinical application of TRAIL is limited by its short serum half-life and inefficient in vivo delivery methods.
Purpose of the Study:
- To develop a targeted nanoparticle (NP) system for efficient delivery of TRAIL-encoding plasmid DNA to glioblastoma (GBM).
- To evaluate the in vitro and in vivo efficacy of the developed NP-TRAIL-CTX system in GBM treatment.
Main Methods:
- Development of targeted iron oxide NPs coated with chitosan-polyethylene glycol-polyethyleneimine copolymer and chlorotoxin (CTX).
- In vitro assessment of NP-TRAIL delivery into T98G GBM cells and TRAIL secretion.
- In vivo evaluation of NP-TRAIL-CTX efficacy in mice with T98G-derived flank xenografts.
Main Results:
- NP-TRAIL effectively delivered TRAIL into T98G GBM cells, inducing significant TRAIL secretion (40 pg mL(-1) in vitro).
- TRAIL-transfected cells exhibited a threefold increase in apoptosis compared to control NP-treated cells.
- Systemic administration of NP-TRAIL-CTX in mice led to near-zero tumor growth and induced apoptosis in tumor tissues.
Conclusions:
- The developed NP-TRAIL-CTX system demonstrates effective targeted delivery of TRAIL to GBM.
- This nanoparticle-based approach holds potential as a targeted anticancer therapeutic for glioblastoma.
More Related Videos
07:25Author Spotlight: Multimodal Imaging Strategies for Optimizing Drug Delivery and Early Detection in Glioblastoma Treatment
Published on: March 1, 2024
14:10Contrast Ultrasound Targeted Treatment of Gliomas in Mice via Drug-Bearing Nanoparticle Delivery and Microvascular Ablation
Published on: December 15, 2010
